原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)

Chinese expert consensus on management of intrahepatic cholangiocarcinoma(2022 edition)

肝内胆管癌(ICC)近年来发病率呈明显上升趋势,亚洲人群发病率明显高于欧美人群,因此,临床上越来越受到重视。复杂的疾病特征和预后是ICC治疗的极大挑战。为更好地指导ICC诊断与治疗和改善患者生存,中国抗癌协会肝癌专业委员会胆管癌协作组梳理ICC诊断与治疗相关证据,结合临床实践,撰写《原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)》。本共识内容聚焦于ICC的筛查与诊断、病理学诊断及分子分型、多学科综合诊疗、外科治疗、局部治疗、系统治疗,旨在提高临床医师对ICC的诊断与治疗能力,使患者最大获益。

In recent years,the incidence rate of intrahepatic cholangiocarcinoma(ICC)has shown an obvious upward trend and the incidence rate of Asian population is higher than that of European and American population,therefore it has drawn more attention in clinical practice.The complexity of characteristics and prognosis of ICC form a great challenge to the treatment of ICC.In order to better guide the diagnosis and treatment of ICC and improve the survival rate of the disease,experts of the Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group review the relevant evidence in combination with the actual clinical situation and propose the Chinese expert consensus on management of intrahepatic cholangiocarcinoma(2022 edition).The consensus has focused on the screening and diagnosis,pathological and molecular typing,multidisciplinary diagnosis and treatment surgical therapy,local and systemic therapy of ICC,aiming to improve the ability of clinicians to diagnose and treat ICC,so that patients can obtain the maximum clinical benefit from the treatment.